MX2020009907A - Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular. - Google Patents

Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular.

Info

Publication number
MX2020009907A
MX2020009907A MX2020009907A MX2020009907A MX2020009907A MX 2020009907 A MX2020009907 A MX 2020009907A MX 2020009907 A MX2020009907 A MX 2020009907A MX 2020009907 A MX2020009907 A MX 2020009907A MX 2020009907 A MX2020009907 A MX 2020009907A
Authority
MX
Mexico
Prior art keywords
cell culture
glycoforms
antibodies produced
taf
total afucosylated
Prior art date
Application number
MX2020009907A
Other languages
English (en)
Inventor
Prince Bhebe
Matthew Jerums
Irene Liu
Kurt Kunas
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2020009907A publication Critical patent/MX2020009907A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan en la presente métodos de producción de una composición de anticuerpo que comprende un nivel deseado o predeterminado o preseleccionado de glicoformas afucosiladas totales (TAF). En realizaciones a modo de ejemplo, el método comprende mantener células de glicosilación competente en un medio de cultivo celular que comprende fucosa y/o glucosa a una concentración específica tal como se describe en la presente, dependiendo del nivel de glicoformas TAF deseado. También se proporcionan en la presente composiciones relacionadas que comprenden proteínas glicosiladas y glicoformas TAF de las mismas. También se proporcionan medios de cultivo celular.
MX2020009907A 2018-03-26 2019-03-26 Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular. MX2020009907A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648308P 2018-03-26 2018-03-26
PCT/US2019/024154 WO2019191150A1 (en) 2018-03-26 2019-03-26 Total afucosylated glycoforms of antibodies produced in cell culture

Publications (1)

Publication Number Publication Date
MX2020009907A true MX2020009907A (es) 2020-10-14

Family

ID=66102281

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020009907A MX2020009907A (es) 2018-03-26 2019-03-26 Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular.
MX2025015600A MX2025015600A (es) 2018-03-26 2020-09-22 Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025015600A MX2025015600A (es) 2018-03-26 2020-09-22 Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular

Country Status (15)

Country Link
US (2) US12325737B2 (es)
EP (1) EP3775251A1 (es)
JP (2) JP2021519068A (es)
KR (2) KR20200135781A (es)
CN (2) CN111954719B (es)
AU (2) AU2019243848B2 (es)
BR (1) BR112020019559A2 (es)
CA (1) CA3093853A1 (es)
CL (1) CL2020002450A1 (es)
EA (1) EA202092286A1 (es)
IL (2) IL276910B2 (es)
MA (1) MA52186A (es)
MX (2) MX2020009907A (es)
SG (1) SG11202009216YA (es)
WO (1) WO2019191150A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
KR20220115998A (ko) * 2019-12-19 2022-08-19 메르크 파텐트 게엠베하 단백질의 글리코실화 프로파일을 조절하기 위한 방법 및 조성물
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113960232B (zh) * 2021-10-28 2024-02-20 苏州大学 一种基于唾液特异性岩藻糖基化结构糖谱及其检测方法和应用
WO2024220916A1 (en) * 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5714465A (en) 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US6630143B1 (en) 1993-05-24 2003-10-07 Immunex Corporation Antibodies against flt3 ligand
US7045128B2 (en) 1993-05-24 2006-05-16 Immunex Corporation Antibodies against flt3-ligand
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
IL127872A0 (en) 1996-07-19 1999-10-28 Amgen Inc Analogs of cationic proteins
US6242213B1 (en) 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
EP0975754B2 (en) 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU742757C (en) 1997-12-17 2007-05-17 Immunex Corporation Cell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides
WO1999032626A1 (en) 1997-12-23 1999-07-01 Immunex Corporation Sigirr dna and polypeptides
WO1999033878A1 (en) 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
AU750767B2 (en) 1998-01-23 2002-07-25 Immunex Corporation ACPL DNA and polypeptides
NZ510356A (en) 1998-08-07 2004-12-24 Immunex Corp Molecules designated LDCAM
IL140938A0 (en) 1998-08-07 2002-02-10 Immunex Corp Molecules designated b7l-1
IL143034A0 (en) 1998-11-13 2002-04-21 Immunex Corp Human tslp dna and polypeptides
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
DE60138715D1 (de) 2000-09-05 2009-06-25 Amgen Inc Tnf-rezeptor-ähnliche moleküle und deren anwendungen
BRPI0116728B1 (pt) 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US6887687B2 (en) 2001-07-30 2005-05-03 Immunex Corporation Nucleic acids encoding human ataxin-1-like polypeptide IMX97018
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002351204B2 (en) 2001-12-03 2008-07-10 Abgenix, Inc. Anti-CD45RB antibodies for use in treating autoimmune disease and transplant rejection
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1467756A4 (en) 2001-12-28 2007-03-21 Abgenix Inc METHODS OF USING ANTI-MUC18 ANTIBODIES
AU2002361887A1 (en) 2001-12-28 2003-07-24 Abgenix, Inc. Use of antibodies against the muc18 antigen
CA2471849A1 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
CA2496419A1 (en) 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
CA2824167C (en) 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
ATE472597T2 (de) 2003-05-15 2010-07-15 Wyeth Llc Kontrollierte glukosezufuhr für tierzellkultur
CN102558352A (zh) 2003-06-27 2012-07-11 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
CN102408483B (zh) 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
EP1648935A2 (en) 2003-07-25 2006-04-26 Amgen Inc. Antagonists and agonists of ldcam and methods of use
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
WO2005016111A2 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MXPA06004853A (es) 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
WO2005118643A2 (en) 2004-04-23 2005-12-15 Amgen Inc. Antibodies to angiogenesis inhibiting domains of cd148
EA200601972A1 (ru) 2004-04-23 2007-08-31 Амджен Инк. Антитела к ингибирующим ангиогенез доменам cd148
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
EP3058955B1 (en) 2005-03-24 2019-05-29 Millennium Pharmaceuticals, Inc. Antibodies that bind ov064 and methods of use therefor
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1885847B1 (en) 2005-05-26 2011-07-06 Cytos Biotechnology AG Scalable fermentation process
AU2006270009A1 (en) 2005-07-18 2007-01-25 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CA2621371C (en) 2005-09-07 2018-05-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
ES2385054T3 (es) 2005-12-13 2012-07-17 Medimmune Limited Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
WO2008060331A2 (en) 2006-05-19 2008-05-22 Amgen Inc. Antibodies to sars coronavirus
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TWI456062B (zh) 2006-09-13 2014-10-11 Abbvie Inc 細胞培養改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CA2663536A1 (en) 2006-10-24 2008-05-02 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
UY30994A1 (es) 2007-04-02 2008-11-28 Amgen Fremont Inc Anticuerpos anti-ige
EP2528002B1 (en) 2007-04-16 2015-11-04 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
ES2650224T3 (es) 2007-08-21 2018-01-17 Amgen, Inc. Proteínas de unión al antígeno C-FMS humano
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
DK2438171T3 (en) 2009-06-02 2015-01-26 Regeneron Pharma Fucosylerings-deficient cells
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
BR112012025645A2 (pt) 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013013013A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
WO2013114164A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013114167A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of obtaining glycoform composition
US9283371B2 (en) 2012-02-29 2016-03-15 Thu-Ha Duncan Electro-stimulation system
CN103320388B (zh) * 2012-03-20 2015-10-28 无锡药明康德生物技术股份有限公司 提高抗体表达量和改良糖基化水平的细胞培养方法
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
NO2760138T3 (es) 2012-10-01 2018-08-04
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
KR102062784B1 (ko) * 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
WO2015128793A1 (en) 2014-02-25 2015-09-03 Dr. Reddy’S Laboratories Limited A process for modifying high mannose and galactosylation content of a glycoprotein composition
HRP20200100T1 (hr) * 2014-02-27 2020-04-03 F. Hoffmann - La Roche Ag Modulacija rasta i glikozilacije stanica u rekombinantnoj proizvodnji glikoproteina
WO2015140708A1 (en) 2014-03-19 2015-09-24 Pfizer Inc. Method of cell culture
WO2015140700A1 (en) 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
US20160115225A1 (en) 2014-10-24 2016-04-28 Abbvie Inc. Methods of Reducing Methylglyoxal (MGO) Modification of Recombinant Proteins in Cell Culture
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
WO2017079165A1 (en) * 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
EP3374514A1 (en) 2015-11-11 2018-09-19 Ares Trading S.A. Methods for modulating production profiles of recombinant proteins
US20190161543A1 (en) * 2016-01-06 2019-05-30 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
EP3400242A1 (en) 2016-01-06 2018-11-14 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species, and fragments in a monoclonal antibody composition
WO2017134667A1 (en) * 2016-02-02 2017-08-10 Insight Biopharmaceuticals Ltd. Methods of generating antibodies

Also Published As

Publication number Publication date
JP2024019717A (ja) 2024-02-09
US20250197479A1 (en) 2025-06-19
CN111954719B (zh) 2025-07-18
AU2019243848A1 (en) 2020-09-17
BR112020019559A2 (pt) 2021-01-12
KR20200135781A (ko) 2020-12-03
AU2024278151A1 (en) 2025-01-02
EA202092286A1 (ru) 2021-03-18
IL276910B2 (en) 2025-11-01
MX2025015600A (es) 2026-02-03
CN111954719A (zh) 2020-11-17
IL313983A (en) 2024-08-01
MA52186A (fr) 2021-02-17
IL276910B1 (en) 2024-08-01
SG11202009216YA (en) 2020-10-29
CL2020002450A1 (es) 2020-12-28
CA3093853A1 (en) 2019-10-03
CN119639849A (zh) 2025-03-18
US20210079065A1 (en) 2021-03-18
IL276910A (en) 2020-10-29
JP2021519068A (ja) 2021-08-10
EP3775251A1 (en) 2021-02-17
US12325737B2 (en) 2025-06-10
WO2019191150A1 (en) 2019-10-03
AU2019243848B2 (en) 2025-01-02
KR20260011202A (ko) 2026-01-22

Similar Documents

Publication Publication Date Title
MX2025015600A (es) Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular
EP4410986A3 (en) Cells, vertebrates, populations & methods
ATE440949T1 (de) Gesteuertes überlesen von stopcodons
ZA200703124B (en) System and method for production of antibodies in plant cell culture
EA201992795A1 (ru) Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе
WO2006029198A3 (en) Culturing human embryonic stem cells
WO2006133148A3 (en) Method of producing antibodies with modified fucosylation level
EP2348126A3 (en) Production of anti-amyloid beta antibodies
ATE500331T1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
EP2471906A3 (en) Placental stem cell populations
NZ592159A (en) Means and methods for influencing the stability of antibody producing cells
WO2010059902A3 (en) 3d cell-culture article and methods thereof
WO2016077734A3 (en) Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors
WO2008045962A3 (en) Methods and materials related to anti-a (beta) antibodies
WO2022046804A3 (en) Compositions and methods for assaying proteins and nucleic acids
WO2009139930A3 (en) Antibodies and processes for preparing the same
AU2019268061A1 (en) Placental stem cell populations
AU2019326179A8 (en) Method for producing intestinal tract nerve precursor cell
WO2005113795A3 (en) Hematology reference control containing an immature granulocyte component
EP1687413B8 (en) Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease
WO2022192249A3 (en) Compositions and methods for assessing and treating t cell dysfunction
WO2010002160A3 (ko) 돼지의 알파에스 1 카제인 유전자, 그 프로모터 및 그의 용도
WO2007117763A3 (en) Methods and compositions for targeting relt
ATE514784T1 (de) Zellpräparation
WO2008090290A3 (fr) Milieu de culture synthétique chimiquement défini